JAK Inhibition in the Treatment of Alopecia Areata: A Promising New Dawn?

    Fathima Ferial Ismail, Rodney Sinclair
    TLDR JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
    The document reviewed the potential of JAK inhibitors in treating alopecia areata (AA), a T-cell-mediated disease causing hair loss and nail dystrophy. It highlighted six JAK inhibitors— tofacitinib, ruxolitinib, baricitinib, CTP-543, PF-06651600, and PF-06700841— which showed promise in regrowing hair and reversing nail dystrophy in patients with refractory AA. Early clinical trials yielded positive results, leading to phase 3 trials and optimism among patients. However, the review noted the need for further research to determine optimal dosing, treatment duration, and the necessity of maintenance therapy. Common adverse effects included increased infection risk and laboratory abnormalities.
    Discuss this study in the Community →

    Research cited in this study

    42 / 42 results

    Related Community Posts Join

    6 / 44 results

    Related Research

    4 / 4 results